Published in Telemedicine Week, July 12th, 2005
The original agreement granted Mallinckrodt an exclusive license to market and distribute NeutroSpec worldwide, excluding Europe. Under the terms of the amendment, Mallinckrodt and Palatin will jointly develop and commercialize NeutroSpec for all global markets. Tyco and Palatin are working to develop an international regulatory strategy. Financial terms of the amended agreement were not disclosed.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Telemedicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.